Fibrin-Binding Apyrase for Targeted Thrombus Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thrombotic disorders, such as stroke and myocardial infarction, face limitations due to significant risks of bleeding complications, and existing antiplatelet agents often interfere with platelet adhesion and clot retraction, necessitating the development of novel strategies that inhibit platelet activation and aggregation with minimal bleeding risks.
Innovation Solution
The use of ADPase enhanced apyrases, derived from enzymes like CD39, CD39L1, CD39L2, CD39L3, and CD39L4, which are administered in soluble form to inhibit platelet aggregation by metabolizing ADP, thereby preventing thrombus formation without causing excessive bleeding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological treatments (anti-coagulants, thrombolytic agents, antiplatelet agents) are used to treat thrombotic disorders, then thrombus formation is inhibited, but bleeding complications significantly increase
Solution Approach 1:
The patent applies local quality by creating a thrombus-targeting system where the apyrase enzyme is selectively delivered to and activated at the thrombus site through fibrin binding. This localized action allows ADP metabolism to occur specifically where needed (in the thrombus) while maintaining normal platelet function elsewhere, thereby preventing systemic bleeding complications while still achieving effective thrombus inhibition.
Solution Approach 2:
The patent uses fibrin as an intermediary mediator that binds to the apyrase enzyme and delivers it specifically to the thrombus. The fibrin acts as a bridge between the therapeutic agent (apyrase) and the target (thrombus), enabling selective localization. This intermediary mechanism ensures the drug accumulates at the disease site without causing systemic effects that lead to bleeding.
2Reliability
If antiplatelet agents are used to inhibit platelet aggregation, then thrombotic disorders are prevented, but platelet adhesion and clot retraction are interfered with causing bleeding risks
Solution Approach 1:
The patent segments the platelet activation pathway by specifically targeting ADP-mediated aggregation while leaving other platelet functions intact. By using apyrase to metabolize ADP locally at the thrombus, the invention selectively inhibits the ADP pathway without affecting other platelet mechanisms such as adhesion and clot retraction, thus preventing aggregation-related thrombosis while preserving protective platelet functions.
Solution Approach 2:
The patent changes the biochemical parameter of ADP concentration specifically at the thrombus site through localized metabolism by apyrase. This localized parameter change (reducing ADP levels only where fibrin is present) achieves selective inhibition of ADP-driven platelet aggregation without altering systemic platelet parameters, thereby avoiding the bleeding risks associated with broad-spectrum antiplatelet agents.
3Reliability
If ADPase enhanced apyrases are administered in soluble form to inhibit platelet aggregation, then thrombus formation is prevented, but the risk of excessive bleeding may increase
Solution Approach 1:
The patent transforms the soluble apyrase into a locally-acting agent by conferring fibrin-binding capability. This modification creates local quality by concentrating the enzyme activity specifically at the thrombus site where fibrin is present, rather than allowing diffuse systemic action. The localized enzyme activity metabolizes ADP only where needed, preventing thrombus formation at the target site while avoiding systemic bleeding complications.
Solution Approach 2:
The patent creates a composite therapeutic agent by combining apyrase enzyme with fibrin-binding capability. This composite structure integrates two functional elements: the catalytic activity of apyrase and the targeting capability of fibrin binding. The composite nature allows the drug to self-localize to thrombi through fibrin recognition while maintaining enzymatic function, achieving selective thrombus prevention without systemic bleeding risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ADPase enhanced apyrases effectively inhibit platelet activation and aggregation, reducing the risk of thrombotic disorders like stroke and myocardial infarction while minimizing the risk of bleeding complications, as demonstrated by animal model studies.
Implementation Method 1
ADPase enhanced apyrases, derived from enzymes like CD39, CD39L1, CD39L2, CD39L3, and CD39L4, which are administered in soluble form to inhibit platelet aggregation by metabolizing ADP
Data Source
AI summary
The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals.